Huntington Bancshares
HBAN
$17.90
+1.82%
Huntington Bancshares Inc. is a regional bank holding company operating primarily in the Midwestern United States, providing a comprehensive suite of consumer and commercial banking services, including deposit accounts, lending, payments, investment management, and treasury services. It is a significant player in the U.S. regional banking sector, distinguished by its focus on relationship banking and a strong presence in its core markets. The current investor narrative is centered on navigating the challenging interest rate environment and credit quality concerns typical for the banking industry, with attention on its ability to manage net interest margins and loan growth amidst economic uncertainty.…
HBAN
Huntington Bancshares
$17.90
Investment Opinion: Should I buy HBAN Today?
Rating & Thesis: HBAN is rated a Hold. The core thesis is that the stock presents a value proposition with significant free cash flow, but lacks a near-term catalyst to overcome sector headwinds and earnings volatility, warranting a neutral stance until greater clarity emerges.
Supporting Evidence: This view is supported by four key data points: 1) The attractive forward P/E of 8.85x implies earnings growth and is below typical sector multiples, 2) Robust trailing free cash flow of $2.265 billion supports the 3.96% dividend yield, 3) A solid ROE of 9.08% indicates capital efficiency, and 4) Recent positive price momentum (+11.73% over 3 months) suggests the downtrend may be stabilizing. However, these are counterbalanced by the -17.81% annual underperformance versus the market.
Risks & Conditions: The biggest risks to this thesis are a resurgence of earnings volatility and a deterioration in credit quality. This Hold rating would upgrade to a Buy if the forward P/E compresses further towards 8x while revenue growth stabilizes above 5%, or if the stock sustainably breaks above its 52-week high resistance of $19.46. It would downgrade to a Sell if quarterly EBITDA shows another sequential decline of over 15%, or if the price breaks below the 52-week low of $14.89. Based on its P/E positioning in the middle of its historical range and versus peers, the stock is currently fairly valued.
Sign up to view all
HBAN 12-Month Price Forecast
HBAN is a classic 'show me' story trading at a reasonable valuation with strong underlying cash generation, but burdened by sector malaise and earnings inconsistency. The neutral stance reflects the high probability (50%) of a base-case range-bound trading environment. The stock needs to demonstrate consecutive quarters of stable or growing operating profits (EBITDA) to convince the market that its cash flow is sustainable and warrant a higher multiple. A shift to a bullish stance would require a confirmed break above $19.46 with improving fundamentals; a bearish shift would be triggered by a breakdown below $14.89 with deteriorating credit metrics.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Huntington Bancshares's 12-month outlook, with a consensus price target around $23.27 and implied upside of +30.0% versus the current price.
Average Target
$23.27
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$14 - $23
Analyst target range
Analyst coverage for HBAN appears limited, with data showing only 3 analysts providing estimates, which is below the typical coverage for a large-cap regional bank and may indicate lower institutional interest or a focus on consensus estimates rather than price targets. The available data points to estimated revenue and EPS for a future period, but specific Buy/Hold/Sell ratings and an average price target are not provided in the dataset. The institutional ratings data shows recent activity, with firms like Morgan Stanley (Overweight), Truist (Buy), and JP Morgan (Overweight) maintaining positive ratings, while others like Piper Sandler (Underweight) and Barclays (Equal Weight) hold more cautious views. This mix of opinions, with a slight lean towards bullish calls, suggests moderate but not overwhelming positive sentiment, with the wide dispersion in ratings (from Underweight to Overweight) indicating a lack of strong consensus and higher uncertainty regarding the stock's near-term trajectory.
Bulls vs Bears: HBAN Investment Factors
The evidence presents a balanced but cautiously leaning picture. The bear side currently holds stronger evidence, primarily due to the stock's pronounced long-term underperformance versus the market, earnings volatility, and lack of a clear bullish catalyst reflected in mixed analyst sentiment. However, compelling bull points exist in the form of strong free cash flow, an attractive forward valuation, and recent positive price momentum suggesting a potential bottom. The single most important tension in the investment debate is the resolution of earnings volatility. If the bank can stabilize its EBITDA and demonstrate consistent net interest margin management, the attractive valuation and cash flow could drive a significant re-rating. Conversely, continued earnings pressure would validate the bearish underperformance narrative.
Bullish
- Strong Free Cash Flow Generation: The company generated substantial trailing twelve-month free cash flow of $2.265 billion, providing significant internal capital for dividends, share buybacks, and organic growth. This robust cash generation, coupled with a sustainable payout ratio of ~46%, supports shareholder returns and financial flexibility.
- Attractive Valuation with Forward Earnings Growth: HBAN trades at a forward P/E of 8.85x, which is 24% below its trailing P/E of 11.6x, indicating analysts expect earnings growth. This forward multiple is below typical regional bank averages, suggesting the stock is undervalued relative to its future profit potential.
- Solid Profitability and Capital Efficiency: The bank maintains a healthy net margin of 17.7% and a Return on Equity (ROE) of 9.08%, demonstrating efficient capital deployment. A debt-to-equity ratio of 0.76 indicates a conservative balance sheet, reducing financial risk.
- Recent Positive Price Momentum: The stock has gained 9.06% over the past month and 11.73% over the past three months, signaling a potential reversal from oversold levels. This technical strength, while nascent, suggests improving investor sentiment after a prolonged downtrend.
Bearish
- Pronounced Long-Term Underperformance: HBAN has significantly underperformed the broader market, with a -17.81% relative strength over the past year and a -4.69% return over six months versus the SPY's +9.72% gain. This persistent weakness reflects deep-seated sector and company-specific headwinds.
- Earnings and Margin Volatility: Quarterly EBITDA has shown significant fluctuations, dropping from $941 million in Q3 2025 to $631 million in Q4 2025. This volatility in operating profitability raises concerns about the stability of core earnings amidst interest rate and credit quality pressures.
- Limited Analyst Coverage and Sentiment: Analyst coverage is limited to only 3 firms, indicating lower institutional interest. Sentiment is mixed with ratings ranging from Underweight to Overweight, reflecting a lack of strong consensus and higher uncertainty on the stock's near-term path.
- Trading Near Mid-Range of Historical Valuation: The trailing P/E of 11.6x sits in the middle of its historical range (highs above 18x, lows around 7x), suggesting the market is not pricing in a significant discount for recovery. This middling valuation offers limited multiple expansion potential without a fundamental catalyst.
HBAN Technical Analysis
The stock has been in a pronounced downtrend over the past six months, with a price decline of -4.69% over that period, significantly underperforming the broader market which gained 9.72%. As of the latest close, the price of $16.86 is trading at approximately 13.3% above its 52-week low of $14.89 but remains 13.4% below its 52-week high of $19.46, positioning it in the lower half of its annual range and suggesting a bearish to consolidating phase. Recent momentum, however, shows a notable positive shift; the stock has gained 9.06% over the past month and 11.73% over the past three months, indicating a potential reversal or a relief rally from oversold levels, though this short-term strength has yet to overcome the longer-term downtrend. The stock's beta of 0.969 indicates it has market-like volatility, but its significant underperformance versus the SPY over the past year (-17.81% relative strength) highlights its sector-specific and company-specific headwinds. Key technical levels are clearly defined, with immediate resistance near the 52-week high of $19.46 and strong support at the 52-week low of $14.89; a sustained break above the recent February high near $19.27 would signal a more convincing trend reversal, while a break below $14.89 would confirm a continuation of the downtrend.
Beta
0.97
0.97x market volatility
Max Drawdown
-22.1%
Largest decline past year
52-Week Range
$15-$19
Price range past year
Annual Return
+10.0%
Cumulative gain past year
| Period | HBAN Return | S&P 500 |
|---|---|---|
| 1m | +11.5% | -2.2% |
| 3m | +18.7% | +15.8% |
| 6m | +0.9% | +6.4% |
| 1y | +10.0% | +20.9% |
| ytd | +2.4% | +7.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HBAN Fundamental Analysis
Revenue has shown modest but steady growth, with the most recent Q4 2025 figure at $3.247 billion, representing a 5.8% year-over-year increase. This growth, however, appears to have decelerated from the stronger sequential performance seen in Q3 2025 ($3.228B) and Q2 2025 ($3.027B), suggesting a potential plateauing in the top line. The company is profitable, reporting Q4 2025 net income of $519 million and a trailing twelve-month net margin of 17.7%. Gross margin for the quarter was a healthy 63.2%, but operating profitability, as indicated by the quarterly EBITDA of $631 million, has fluctuated, showing some compression from the prior quarter's $941 million. The balance sheet and cash flow position appear solid; the company maintains a reasonable debt-to-equity ratio of 0.76 and generated substantial trailing free cash flow of $2.265 billion. This strong free cash flow, coupled with a return on equity (ROE) of 9.08%, suggests the bank is generating sufficient internal capital to support operations, fund its dividend (payout ratio of ~46%), and potentially pursue growth without excessive reliance on external financing.
Quarterly Revenue
$3.2B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.63%
Latest Quarter
Free Cash Flow
$2.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HBAN Overvalued?
Given the positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The stock trades at a trailing P/E of 11.6x and a forward P/E of 8.85x, based on estimated EPS. The forward P/E being 24% lower than the trailing multiple suggests analysts anticipate earnings growth in the coming year. Compared to typical regional bank valuations, a trailing P/E of 11.6x appears to be at or slightly below the sector average, indicating the stock is not trading at a significant premium. Historically, the stock's own P/E ratio has ranged widely; the current trailing P/E of 11.6x sits near the middle of its multi-year historical range, which has seen highs above 18x and lows around 7x. This positioning suggests the market is not pricing in excessive optimism nor extreme pessimism, but rather a valuation that reflects the current challenging operating environment for regional banks.
PE
12.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -268x~19x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HBAN faces risks from earnings volatility, as evidenced by the 33% quarter-over-quarter decline in EBITDA from Q3 to Q4 2025. While the debt-to-equity ratio of 0.76 is manageable, the bank's profitability is inherently tied to the interest rate environment and credit quality, which are currently uncertain. Revenue growth deceleration to 5.8% YoY in Q4, down from stronger sequential quarters, poses a risk to the valuation which depends on stable earnings growth, as implied by the forward P/E of 8.85x.
Market & Competitive Risks: The stock trades with a beta of 0.969, indicating market-like volatility, but has significantly underperformed the SPY by -17.81% over the past year, highlighting acute sector-specific risks. These include potential valuation compression if regional bank sentiment deteriorates further, despite the current P/E being near the sector average. Competitive pressures for deposits and loans in its core Midwestern markets could further pressure net interest margins. The wide dispersion in analyst ratings (Underweight to Overweight) underscores the high uncertainty and lack of consensus, which itself is a market risk.
Worst-Case Scenario: The most damaging scenario involves a severe economic downturn in the Midwestern U.S., leading to a sharp rise in loan defaults and a collapse in net interest margins. This could trigger analyst downgrades, a dividend cut if the payout ratio becomes unsustainable, and a flight of investor capital from the regional banking sector. Quantitatively, the realistic downside could see the stock re-testing its 52-week low of $14.89, representing a potential loss of approximately -12% from the current price of ~$16.86. A breach of that level could lead to a drawdown approaching the stock's maximum observed drawdown of -22.06%.
FAQ
The key risks are: 1) Financial/Operational Risk: Earnings volatility, as seen in the 33% QoQ drop in EBITDA to $631 million in Q4 2025. 2) Market/Sector Risk: Persistent underperformance versus the broader market (beta 0.969 but -17.81% relative strength), indicating acute sector headwinds. 3) Credit Risk: Exposure to potential loan defaults in a slowing economy, which could impact profitability. 4) Sentiment Risk: Limited and mixed analyst coverage (only 3 firms, ratings from Underweight to Overweight) reflects low conviction and can lead to heightened volatility on news flow.
The 12-month forecast presents three scenarios with associated probabilities. The Base Case (50% probability) sees the stock trading between $16.50 and $18.50, reflecting range-bound action amid fair valuation. The Bull Case (30% probability) targets a break above the 52-week high to $19.46-$21.00, driven by earnings stabilization and sector tailwinds. The Bear Case (20% probability) risks a re-test of the 52-week low, with a target range of $14.89-$16.00, triggered by credit deterioration. The Base Case is most likely, predicated on the assumption that revenue growth stabilizes in the low single digits and the current valuation multiple holds.
HBAN appears fairly valued to slightly undervalued based on forward earnings. Its forward P/E of 8.85x is 24% below its trailing P/E, implying expected earnings growth and is at or below typical regional bank averages. Historically, its trailing P/E of 11.6x sits in the middle of its own multi-year range, suggesting the market is not pricing in extreme optimism or pessimism. The valuation implies the market expects modest growth but is discounting the stock for sector risks and earnings volatility, offering a fair price for the current fundamentals.
HBAN is a conditional buy for specific investor profiles. For value and income investors seeking exposure to regional banks, its forward P/E of 8.85x and 3.96% dividend yield supported by strong free cash flow are attractive. However, it is not a good buy for growth-oriented investors or those with low risk tolerance, given its significant underperformance versus the market (-17.81% over the past year) and earnings volatility. A good entry point would be on further weakness towards the $15-$16 range, providing a larger margin of safety.
HBAN is more suitable for a long-term investment horizon of 2-3 years minimum. As a regional bank, its fortunes are tied to economic cycles and interest rate policy, which play out over longer periods. Its ~4% dividend yield and strong free cash flow support a total return approach for patient investors waiting for a sector recovery. The stock's market-like volatility (beta 0.969) and recent sharp downtrend make it a poor candidate for short-term trading, as it lacks clear, near-term technical catalysts and is subject to sector-wide sentiment swings.
